Indications -- Hepatitis Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Hepatitis

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: DewDiligence_on_SI who wrote (141)	6/6/2006 3:36:48 AM
From: DewDiligence_on_SI	of 312

Contemporaneous reaction to the Albuferon deal: Albuferon and IDIX’s NM283 are at a similar stage of development, but the deal HGSI got from NVS for Albuferon is not as lucrative as the deal IDIX got from NVS for NM283. HGSI has to pay half of the Albuferon development costs, while NVS pays 100% of the development costs for NM283. (The potential milestones in the two deals are roughly similar.) What’s remarkable is hot many irons NVS has in the HCV fire: a nucleoside polymerase inhibitor (NM283 from IDIX in phase-2b), an immunomodulator to replace interferon (ANA975 from ANDS in phase-1b), a non-nucleoside drug-discovery program with GNLB including the first right on anything actually discovered, and now Albuferon. About the only thing NVS does not have cooking in HCV is a protease inhibitor, and they may be looking to rectify that as we speak.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next